Home

Surichinmoi Re-paste maximum her2 colon cancer Extra fork pace

The predictive role of ERBB2 point mutations in metastatic colorectal cancer:  A systematic review - ScienceDirect
The predictive role of ERBB2 point mutations in metastatic colorectal cancer: A systematic review - ScienceDirect

HER2 expression and copy number alterations in colorectal cancer (CRC)....  | Download Scientific Diagram
HER2 expression and copy number alterations in colorectal cancer (CRC).... | Download Scientific Diagram

PDF] Dual HER2 inhibition strategies in the management of  treatment-refractory metastatic colorectal cancer: History and status |  Semantic Scholar
PDF] Dual HER2 inhibition strategies in the management of treatment-refractory metastatic colorectal cancer: History and status | Semantic Scholar

HER2 in Colorectal Cancer: The Long and Winding Road From Negative  Predictive Factor to Positive Actionable Target | American Society of  Clinical Oncology Educational Book
HER2 in Colorectal Cancer: The Long and Winding Road From Negative Predictive Factor to Positive Actionable Target | American Society of Clinical Oncology Educational Book

Fulfilling the potential of HER2-targeting in colorectal cancer: update on  detection and management - YouTube
Fulfilling the potential of HER2-targeting in colorectal cancer: update on detection and management - YouTube

Dual-targeted therapy with trastuzumab and lapatinib in  treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal  cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2  trial - The Lancet Oncology
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial - The Lancet Oncology

IJMS | Free Full-Text | Beyond RAS and BRAF: HER2, a New Actionable  Oncotarget in Advanced Colorectal Cancer
IJMS | Free Full-Text | Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer

Cancers | Free Full-Text | Molecular Basis of HER2-Targeted Therapy for HER2-Positive  Colorectal Cancer
Cancers | Free Full-Text | Molecular Basis of HER2-Targeted Therapy for HER2-Positive Colorectal Cancer

HER2 and BRAF mutation in colorectal cancer patients: a retrospective study  in Eastern China [PeerJ]
HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China [PeerJ]

A HER2-targeting antibody-MMAE conjugate RC48 sensitizes immunotherapy in  HER2-positive colon cancer by triggering the cGAS-STING pathway | Cell  Death & Disease
A HER2-targeting antibody-MMAE conjugate RC48 sensitizes immunotherapy in HER2-positive colon cancer by triggering the cGAS-STING pathway | Cell Death & Disease

Life | Free Full-Text | HER2 in Metastatic Colorectal Cancer: Pathology,  Somatic Alterations, and Perspectives for Novel Therapeutic Schemes
Life | Free Full-Text | HER2 in Metastatic Colorectal Cancer: Pathology, Somatic Alterations, and Perspectives for Novel Therapeutic Schemes

Anti-HER2 Agents Gain Ground in Colorectal Cancer
Anti-HER2 Agents Gain Ground in Colorectal Cancer

HER2 in Colorectal Cancer: The Long and Winding Road From Negative  Predictive Factor to Positive Actionable Target | American Society of  Clinical Oncology Educational Book
HER2 in Colorectal Cancer: The Long and Winding Road From Negative Predictive Factor to Positive Actionable Target | American Society of Clinical Oncology Educational Book

Dual HER2 Blockade in Patients With HER2-Amplified Metastatic
Dual HER2 Blockade in Patients With HER2-Amplified Metastatic

Dual HER2 Blockade in Patients With HER2-Amplified Metastatic
Dual HER2 Blockade in Patients With HER2-Amplified Metastatic

Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer  (MyPathway): an updated report from a multicentre, open-label, phase 2a,  multiple basket study - The Lancet Oncology
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study - The Lancet Oncology

Frontiers | Remarkable Response of EGFR- and HER2-Amplified Metastatic Colon  Cancer to Pyrotinib After Failed Multiline Treatments: A Case Report and  Literature Review
Frontiers | Remarkable Response of EGFR- and HER2-Amplified Metastatic Colon Cancer to Pyrotinib After Failed Multiline Treatments: A Case Report and Literature Review

Combined targeting of HER-2 and HER-3 represents a promising therapeutic  strategy in colorectal cancer | BMC Cancer | Full Text
Combined targeting of HER-2 and HER-3 represents a promising therapeutic strategy in colorectal cancer | BMC Cancer | Full Text

HER2/neu testing in primary colorectal carcinoma | British Journal of Cancer
HER2/neu testing in primary colorectal carcinoma | British Journal of Cancer

Mechanisms of resistance to anti-epidermal growth factor receptor  inhibitors in metastatic colorectal cancer
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer

Precision Cancer Medicines for Colon Cancer - CancerConnect
Precision Cancer Medicines for Colon Cancer - CancerConnect

HER2 as an Emerging Oncotarget for Colorectal Cancer Treatment After  Failure of Anti‐Epidermal Growth Factor Receptor Therapy | Semantic Scholar
HER2 as an Emerging Oncotarget for Colorectal Cancer Treatment After Failure of Anti‐Epidermal Growth Factor Receptor Therapy | Semantic Scholar

IJMS | Free Full-Text | Beyond RAS and BRAF: HER2, a New Actionable  Oncotarget in Advanced Colorectal Cancer
IJMS | Free Full-Text | Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer

The HER family as therapeutic targets in colorectal cancer - ScienceDirect
The HER family as therapeutic targets in colorectal cancer - ScienceDirect

HER2 and BRAF mutation in colorectal cancer patients: a retrospective study  in Eastern China [PeerJ]
HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China [PeerJ]

HER2 evaluation by immunohistochemistry and fluorescence in situ... |  Download Scientific Diagram
HER2 evaluation by immunohistochemistry and fluorescence in situ... | Download Scientific Diagram

Clinical significance of HER2 and EGFR expression in colorectal cancer  patients with ovarian metastasis | BMC Clinical Pathology | Full Text
Clinical significance of HER2 and EGFR expression in colorectal cancer patients with ovarian metastasis | BMC Clinical Pathology | Full Text

Frontiers | Human Epidermal Growth Factor Receptor 2 Overexpression and  Amplification in Patients With Colorectal Cancer: A Large-Scale  Retrospective Study in Chinese Population
Frontiers | Human Epidermal Growth Factor Receptor 2 Overexpression and Amplification in Patients With Colorectal Cancer: A Large-Scale Retrospective Study in Chinese Population

HER2 Biomarker in Colon Cancer | Know Your Biomarker
HER2 Biomarker in Colon Cancer | Know Your Biomarker

Q&A column - CAP TODAY
Q&A column - CAP TODAY